A patient with multi-line treatment of stage IV lung adenocarcinoma who developed the EGFR G724S resistance mutation after receiving osimertinib was repeatedly evaluated as being in PR after receiving afatinib, and the PFS was more than 9 months [58]. This evidence concerns the gene EGFR and lung adenocarcinoma.